Syndax Pharmaceuticals Inc 8-K

What Happened

• On January 12, 2026, Syndax Pharmaceuticals (SNDX) issued a press release and presented at the 44th Annual J.P. Morgan Healthcare Conference, filing an 8-K (Item 2.02) with preliminary, unaudited financial information for the year and quarter ended December 31, 2025.
• The company reported preliminary U.S. net product revenue of approximately $44 million for Revuforj (revumenib) in the quarter and $125 million for the full year 2025; Niktimvo (axatilimab-csfr) preliminarily generated about $56 million for the quarter and $152 million for the year. Total preliminary cash, cash equivalents and marketable securities were approximately $394 million as of December 31, 2025.

Key Details

• Revuforj (revumenib) preliminary U.S. net product revenue: ~$44M (quarter), ~$125M (year) for period ended 12/31/2025.
• Niktimvo (axatilimab‑csfr) preliminary U.S. net product revenue: ~$56M (quarter), ~$152M (year) for period ended 12/31/2025; Syndax will report its share of net commercial profit with full-year results.
• Preliminary cash, cash equivalents and marketable securities: approximately $394M as of 12/31/2025.
• Figures are preliminary and unaudited; the company indicated it will report audited full-year 2025 results later.

Why It Matters

• These preliminary revenue figures give investors an early view of commercial traction for Syndax’s two marketed products and a snapshot of the company’s liquidity position heading into 2026.
• The Niktimvo number is reported gross; final reported earnings may differ because Syndax will disclose its share of net commercial profit when it files full-year results.
• Because the numbers are unaudited and preliminary, investors should await the company’s audited 2025 results for final confirmed figures.